78 related articles for article (PubMed ID: 16248285)
1. Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis.
Lau SC; Rosa DD; Jayson G
Curr Opin Mol Ther; 2005 Oct; 7(5):493-501. PubMed ID: 16248285
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer.
Seto T; Higashiyama M; Funai H; Imamura F; Uematsu K; Seki N; Eguchi K; Yamanaka T; Ichinose Y
Lung Cancer; 2006 Jul; 53(1):91-6. PubMed ID: 16697074
[TBL] [Abstract][Full Text] [Related]
5. VEGF function in vascular pathogenesis.
Ng YS; Krilleke D; Shima DT
Exp Cell Res; 2006 Mar; 312(5):527-37. PubMed ID: 16330026
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor trap in non small cell lung cancer.
Riely GJ; Miller VA
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4623-7. PubMed ID: 17671153
[TBL] [Abstract][Full Text] [Related]
7. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
Hazarika S; Dokun AO; Li Y; Popel AS; Kontos CD; Annex BH
Circ Res; 2007 Oct; 101(9):948-56. PubMed ID: 17823371
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
9. Endostatin down-regulates soluble guanylate cyclase (sGC) in endothelial cells in vivo: influence of endostatin on vascular endothelial growth factor (VEGF) signaling.
Schmidt A; Wenzel D; Thorey I; Werner S; Fleischmann BK; Bloch W
Endothelium; 2005; 12(5-6):251-7. PubMed ID: 16410224
[TBL] [Abstract][Full Text] [Related]
10. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
Guo Y; Wang S; Hoot DR; Clinton SK
J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
[TBL] [Abstract][Full Text] [Related]
11. [Vascular endothelial growth factor and two types of its receptors in breast cancer].
Shcherbakov AM; Gershteĭn ES; Anurova OA; Kushlinskiĭ NE
Vopr Onkol; 2005; 51(3):317-21. PubMed ID: 16279095
[TBL] [Abstract][Full Text] [Related]
12. Current insights on the biology and clinical aspects of VEGF regulation.
Birk DM; Barbato J; Mureebe L; Chaer RA
Vasc Endovascular Surg; 2008 Dec-2009 Jan; 42(6):517-30. PubMed ID: 18799497
[TBL] [Abstract][Full Text] [Related]
13. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis.
Scaldaferri F; Vetrano S; Sans M; Arena V; Straface G; Stigliano E; Repici A; Sturm A; Malesci A; Panes J; Yla-Herttuala S; Fiocchi C; Danese S
Gastroenterology; 2009 Feb; 136(2):585-95.e5. PubMed ID: 19013462
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis inhibitors in the treatment of lung cancer.
Sun S; Schiller JH
Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
[TBL] [Abstract][Full Text] [Related]
15. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
Epstein RJ
Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
Okita NT; Yamada Y; Takahari D; Hirashima Y; Matsubara J; Kato K; Hamaguchi T; Shirao K; Shimada Y; Taniguchi H; Shimoda T
Jpn J Clin Oncol; 2009 Sep; 39(9):595-600. PubMed ID: 19535387
[TBL] [Abstract][Full Text] [Related]
17. VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene- based discovery of the next generation of angiogenesis targets.
Rudge JS; Thurston G; Davis S; Papadopoulos N; Gale N; Wiegand SJ; Yancopoulos GD
Cold Spring Harb Symp Quant Biol; 2005; 70():411-8. PubMed ID: 16869778
[TBL] [Abstract][Full Text] [Related]
18. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
Roscoe WA; Welsh ME; Carter DE; Karlik SJ
J Neuroimmunol; 2009 Apr; 209(1-2):6-15. PubMed ID: 19233483
[TBL] [Abstract][Full Text] [Related]
19. Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice.
Schmitz V; Vilanueva H; Raskopf E; Hilbert T; Barajas M; Dzienisowicz C; Gorschlüter M; Strehl J; Rabe C; Sauerbruch T; Prieto J; Caselmann WH; Qian C
Gene Ther; 2006 Aug; 13(16):1198-205. PubMed ID: 16617302
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF therapy: a new approach to colorectal cancer therapy.
Carrato A; Gallego-Plazas J; Guillen-Ponce C
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1385-96. PubMed ID: 17069524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
